Pasithea Therapeutics Corp. insider trading

Every open-market purchase and sale by Pasithea Therapeutics Corp.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $203,000 4 trades by 4 insiders 3 months later: median −40.0% (−40.7% vs S&P 500) Insider sales, 5 years $0 0 trades by 0 insiders

Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.

Pasithea Therapeutics Corp. insider open-market trades
Date	Insider	Trade	Shares	Price	Value	1M after	3M after	6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Pasithea Therapeutics Corp.’s insiders pay?

From August 18, 2022 to June 22, 2026, 7 insiders reported 10 open-market purchases and 0 sales not made under a pre-set plan in Pasithea Therapeutics Corp.

Pasithea Therapeutics Corp.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	12 months after their sales	Latest report
Camac Fund, LP	Other	3	—	—	—	September 30, 2022
Steinman Lawrence	Director	2	—	—	—	December 1, 2025
Camac Capital, LLC	Other	1	—	—	—	August 31, 2022
Coastlands Capital LP	10% owner	1	—	—	—	June 22, 2026
Dumesnil Simon	Director	1	—	—	—	December 1, 2025
Leonite Capital LLC	Other	1	—	—	—	August 26, 2022
Marques Tiago	Chief Executive Officer	1	—	—	—	December 1, 2025

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Pasithea Therapeutics Corp. · Funds · Politicians